273 related articles for article (PubMed ID: 31863723)
1. Role of Post-translational Modifications in Alzheimer's Disease.
Ramesh M; Gopinath P; Govindaraju T
Chembiochem; 2020 Apr; 21(8):1052-1079. PubMed ID: 31863723
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
[TBL] [Abstract][Full Text] [Related]
3. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
Haj-Yahya M; Lashuel HA
J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
[TBL] [Abstract][Full Text] [Related]
4. The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development.
Singh R; Hussain J; Kaur A; Jamdare BG; Pathak D; Garg K; Kaur R; Shankar S; Sunkaria A
Ageing Res Rev; 2023 Sep; 90():102002. PubMed ID: 37423542
[TBL] [Abstract][Full Text] [Related]
5. The Involvement of Post-Translational Modifications in Alzheimer's Disease.
Marcelli S; Corbo M; Iannuzzi F; Negri L; Blandini F; Nistico R; Feligioni M
Curr Alzheimer Res; 2018 Feb; 15(4):313-335. PubMed ID: 28474569
[TBL] [Abstract][Full Text] [Related]
6. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
Marcus JN; Schachter J
J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
[TBL] [Abstract][Full Text] [Related]
7. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.
Wesseling H; Mair W; Kumar M; Schlaffner CN; Tang S; Beerepoot P; Fatou B; Guise AJ; Cheng L; Takeda S; Muntel J; Rotunno MS; Dujardin S; Davies P; Kosik KS; Miller BL; Berretta S; Hedreen JC; Grinberg LT; Seeley WW; Hyman BT; Steen H; Steen JA
Cell; 2020 Dec; 183(6):1699-1713.e13. PubMed ID: 33188775
[TBL] [Abstract][Full Text] [Related]
8. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry.
Kelley AR; Bach SBH; Perry G
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2040-2047. PubMed ID: 30481587
[TBL] [Abstract][Full Text] [Related]
9. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery.
Bai B; Vanderwall D; Li Y; Wang X; Poudel S; Wang H; Dey KK; Chen PC; Yang K; Peng J
Mol Neurodegener; 2021 Aug; 16(1):55. PubMed ID: 34384464
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.
Ahmed T; Zahid S; Mahboob A; Farhat SM
Curr Neuropharmacol; 2017; 15(4):480-494. PubMed ID: 27012953
[TBL] [Abstract][Full Text] [Related]
11. Current Technologies Unraveling the Significance of Post-Translational Modifications (PTMs) as Crucial Players in Neurodegeneration.
Zafar S; Fatima SI; Schmitz M; Zerr I
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254718
[TBL] [Abstract][Full Text] [Related]
12. Tau seeds are subject to aberrant modifications resulting in distinct signatures.
Tseng JH; Ajit A; Tabassum Z; Patel N; Tian X; Chen Y; Prevatte AW; Ling K; Rigo F; Meeker RB; Herring LE; Cohen TJ
Cell Rep; 2021 Apr; 35(4):109037. PubMed ID: 33910013
[TBL] [Abstract][Full Text] [Related]
13. JUMPptm: Integrated software for sensitive identification of post-translational modifications and its application in Alzheimer's disease study.
Poudel S; Vanderwall D; Yuan ZF; Wu Z; Peng J; Li Y
Proteomics; 2023 Feb; 23(3-4):e2100369. PubMed ID: 36094355
[TBL] [Abstract][Full Text] [Related]
14. Post-translational modifications in Alzheimer's disease and the potential for new biomarkers.
Russell CL; Koncarevic S; Ward MA
J Alzheimers Dis; 2014; 41(2):345-64. PubMed ID: 24662105
[TBL] [Abstract][Full Text] [Related]
15. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
[TBL] [Abstract][Full Text] [Related]
16. Post-translational modifications of tau protein in Alzheimer's disease.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
[TBL] [Abstract][Full Text] [Related]
17. Mapping Post-Translational Modifications in Brain Regions in Alzheimer's Disease Using Proteomics Data Mining.
Deolankar SC; Patil AH; Rex DAB; Subba P; Mahadevan A; Prasad TSK
OMICS; 2021 Aug; 25(8):525-536. PubMed ID: 34255573
[TBL] [Abstract][Full Text] [Related]
18. A validated antibody panel for the characterization of tau post-translational modifications.
Ercan E; Eid S; Weber C; Kowalski A; Bichmann M; Behrendt A; Matthes F; Krauss S; Reinhardt P; Fulle S; Ehrnhoefer DE
Mol Neurodegener; 2017 Nov; 12(1):87. PubMed ID: 29157277
[TBL] [Abstract][Full Text] [Related]
19. Post-translational modifications of tau protein: implications for Alzheimer's disease.
Martin L; Latypova X; Terro F
Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
[TBL] [Abstract][Full Text] [Related]
20. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
Thomas SN; Yang AJ
Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
